Article
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial.
The Lancet. Oncology - 1 Jul 2017
Davies Michael A, Saiag Philippe, Robert Caroline, Grob Jean-Jacques, Flaherty Keith T, Arance Ana, Chiarion-Sileni Vanna, Thomas Luc, Lesimple Thierry, Mortier Laurent, Moschos Stergios J, Hogg David, Márquez-Rodas Iván, Del Vecchio Michele, Lebbé Céleste, Meyer Nicolas, Zhang Ying, Huang Yingjie, Mookerjee Bijoyesh, Long Georgina V
Abstract excerpt
BACKGROUND: Dabrafenib plus trametinib improves clinical outcomes in BRAFV600-mutant metastatic melanoma without brain metastases; however, the activity of dabrafenib plus trametinib has not been studied in active melanoma brain metastases. Here, we report results from the phase 2 COMBI-MB trial. Our aim was to build on the current body of evidence of targeted therapy in melanoma brain metastases through an...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.